Skip to main content
Fig. 2 | One Health Advances

Fig. 2

From: Changing antimicrobial resistance profile of Enterobacter spp. isolates in hospitals across China: a seven-year analysis from the CHINET antimicrobial resistance surveillance program (2015–2021)

Fig. 2

Resistance rates of Enterobacter strains to antimicrobial agents from 2015 to 2021. AK, amikacin; CN, gentamicin; IMP, imipenem; MEM, meropenem; FEP, cefepime; CZ, ceftazidime; CRO, ceftriaxone; CTX, cefotaxime; SCF, cefoperazone-sulbactam; FOX, cefoxitin; CXM, cefuroxime; KZ, cefazolin; TZP, piperacillin-tazobactam; AMP, ampicillin; SAM, ampicillin-sulbactam; CIP, ciprofloxacin; NIT, nitrofurantoin; TGC, tigecycline; PB, polymyxins B; SXT, sulfamethoxazole-trimethoprim

Back to article page

One Health Advances

ISSN: 2731-9970

Contact us